Last reviewed · How we verify
methoxypsoralen
methoxypsoralen is a Small molecule drug developed by European Organisation for Research and Treatment of Cancer - EORTC. It is currently in discontinued development.
Methoxypsoralen is a small molecule used in combination with ultraviolet light A in extracorporeal photopheresis, a treatment approach studied for various conditions including COVID-19, lymphoma, and chronic graft versus host disease. It is also used in combination with pegylated interferon α-2b in some clinical trials.
At a glance
| Generic name | methoxypsoralen |
|---|---|
| Sponsor | European Organisation for Research and Treatment of Cancer - EORTC |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | discontinued |
Approved indications
Common side effects
Key clinical trials
- Pilot Study of Pegylated Interferon-Alfa 2b in Combination With PUVA Therapy in Cutaneous T-Cell Lymphoma (NA)
- Addition of Etanercept and Extracorporeal Photopheresis to Standard GVHD Prophylaxis in Patients Undergoing Reduced Intensity Unrelated Donor Hematopoietic Stem Cell Transplant (Phase 2)
- A Randomized Phase 2/3 Multi-Center Study of SM-88 in Subjects With Pancreatic Cancer Whose Disease Has Progressed or Recurred (Phase 2)
- OASIS: Phase II Trial of OrAl SM-88 in Patients With Metastatic Hormone Receptor-posItive HER2-negative (HR+/HER2-) breaSt Cancer (Phase 2)
- A Phase II, Multicenter, Randomized, Double-blind, "Sham" Pheresis-controlled, Study of Extracorporeal Photoimmune Therapy With UVADEX for the Treatment of Rheumatoid Arthritis in Patients Who Have an (Phase 2)
- A Randomized Single-Blind Study of Extracorporeal Photoimmune Therapy With UVADEX in Conjunction With Standard Therapy Alone for the Treatment of Patients With Corticosteroid-Refractory, Corticosteroi (Phase 2)
- Study Comparing the Effectiveness of Narrow-band UVB vs. Bath-PUVA and Narrow-band UVB + Salt Water Baths in Atopic Dermatitis (NA)
- Multicenter Analysis of Efficacy and Outcomes of Extracorporeal Photopheresis as Treatment of Chronic Lung Allograft Dysfunction (N/A)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- methoxypsoralen CI brief — competitive landscape report
- methoxypsoralen updates RSS · CI watch RSS
- European Organisation for Research and Treatment of Cancer - EORTC portfolio CI
Frequently asked questions about methoxypsoralen
What is methoxypsoralen?
Who makes methoxypsoralen?
What development phase is methoxypsoralen in?
Related
- Manufacturer: European Organisation for Research and Treatment of Cancer - EORTC — full pipeline
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing